The self-association coiled-coil domain of PML is sufficient for the oncogenic conversion of the retinoic acid receptor (RAR) alpha

M. Occhionorelli, F. Santoro, I. Pallavicini, A. Gruszka, S. Moretti, D. Bossi, A. Viale, D. Shing, S. Ronzoni, I. Muradore, M. Soncini, G. Pruneri, P. Rafaniello, G. Viale, P. G. Pelicci, S. Minucci

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

In acute promyelocytic leukemia (APL) the retinoic acid receptor alpha (RARα) becomes an oncogene through the fusion with several partners, mostly with promyelocytic leukemia protein (PML), all of which have in common the presence of a self-association domain. The new fusion proteins, therefore, differently from the wild-type RARα, which forms only heterodimers with retinoic X receptor alpha, are also able to homo-oligomerize. The presence of such a domain has been suggested to be crucial for the leukemogenic potential of the chimeric proteins found in APL blasts. Whether or not any self-association domain is sufficient to bestow a leukemogenic activity on RARα is still under investigation. In this work, we address this question using two different X-RARα chimeras, where X represents the coiled-coil domain of PML (CC-RARα) or the oligomerization portion of the yeast transcription factor GCN4 (GCN4-RARα). We demonstrate that in vitro both proteins have transforming potential, and recapitulate the main PML-RARα biological properties, but CC-RARα is uniquely able to disrupt PML nuclear bodies. Indeed, in vivo only the CC-RARα chimera induces efficiently APL in a murine transplantation model. Thus, the PML CC domain represents the minimal structural determinant indispensable to transform RARα into an oncogenic protein.

Original languageEnglish
Pages (from-to)814-820
Number of pages7
JournalLeukemia
Volume25
Issue number5
DOIs
Publication statusPublished - May 2011

Fingerprint

Retinoic Acid Receptors
Acute Promyelocytic Leukemia
Oncogene Fusion
Proteins
Promyelocytic Leukemia Protein
Retinoic Acid Receptor alpha
Transcription Factors
Yeasts
Transplantation

Keywords

  • APL
  • CCR
  • coiled-coil
  • GCR
  • PR
  • RARa oligomerization

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

The self-association coiled-coil domain of PML is sufficient for the oncogenic conversion of the retinoic acid receptor (RAR) alpha. / Occhionorelli, M.; Santoro, F.; Pallavicini, I.; Gruszka, A.; Moretti, S.; Bossi, D.; Viale, A.; Shing, D.; Ronzoni, S.; Muradore, I.; Soncini, M.; Pruneri, G.; Rafaniello, P.; Viale, G.; Pelicci, P. G.; Minucci, S.

In: Leukemia, Vol. 25, No. 5, 05.2011, p. 814-820.

Research output: Contribution to journalArticle

@article{1f2c404913db4614b96ffdc570933fa3,
title = "The self-association coiled-coil domain of PML is sufficient for the oncogenic conversion of the retinoic acid receptor (RAR) alpha",
abstract = "In acute promyelocytic leukemia (APL) the retinoic acid receptor alpha (RARα) becomes an oncogene through the fusion with several partners, mostly with promyelocytic leukemia protein (PML), all of which have in common the presence of a self-association domain. The new fusion proteins, therefore, differently from the wild-type RARα, which forms only heterodimers with retinoic X receptor alpha, are also able to homo-oligomerize. The presence of such a domain has been suggested to be crucial for the leukemogenic potential of the chimeric proteins found in APL blasts. Whether or not any self-association domain is sufficient to bestow a leukemogenic activity on RARα is still under investigation. In this work, we address this question using two different X-RARα chimeras, where X represents the coiled-coil domain of PML (CC-RARα) or the oligomerization portion of the yeast transcription factor GCN4 (GCN4-RARα). We demonstrate that in vitro both proteins have transforming potential, and recapitulate the main PML-RARα biological properties, but CC-RARα is uniquely able to disrupt PML nuclear bodies. Indeed, in vivo only the CC-RARα chimera induces efficiently APL in a murine transplantation model. Thus, the PML CC domain represents the minimal structural determinant indispensable to transform RARα into an oncogenic protein.",
keywords = "APL, CCR, coiled-coil, GCR, PR, RARa oligomerization",
author = "M. Occhionorelli and F. Santoro and I. Pallavicini and A. Gruszka and S. Moretti and D. Bossi and A. Viale and D. Shing and S. Ronzoni and I. Muradore and M. Soncini and G. Pruneri and P. Rafaniello and G. Viale and Pelicci, {P. G.} and S. Minucci",
year = "2011",
month = "5",
doi = "10.1038/leu.2011.18",
language = "English",
volume = "25",
pages = "814--820",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - The self-association coiled-coil domain of PML is sufficient for the oncogenic conversion of the retinoic acid receptor (RAR) alpha

AU - Occhionorelli, M.

AU - Santoro, F.

AU - Pallavicini, I.

AU - Gruszka, A.

AU - Moretti, S.

AU - Bossi, D.

AU - Viale, A.

AU - Shing, D.

AU - Ronzoni, S.

AU - Muradore, I.

AU - Soncini, M.

AU - Pruneri, G.

AU - Rafaniello, P.

AU - Viale, G.

AU - Pelicci, P. G.

AU - Minucci, S.

PY - 2011/5

Y1 - 2011/5

N2 - In acute promyelocytic leukemia (APL) the retinoic acid receptor alpha (RARα) becomes an oncogene through the fusion with several partners, mostly with promyelocytic leukemia protein (PML), all of which have in common the presence of a self-association domain. The new fusion proteins, therefore, differently from the wild-type RARα, which forms only heterodimers with retinoic X receptor alpha, are also able to homo-oligomerize. The presence of such a domain has been suggested to be crucial for the leukemogenic potential of the chimeric proteins found in APL blasts. Whether or not any self-association domain is sufficient to bestow a leukemogenic activity on RARα is still under investigation. In this work, we address this question using two different X-RARα chimeras, where X represents the coiled-coil domain of PML (CC-RARα) or the oligomerization portion of the yeast transcription factor GCN4 (GCN4-RARα). We demonstrate that in vitro both proteins have transforming potential, and recapitulate the main PML-RARα biological properties, but CC-RARα is uniquely able to disrupt PML nuclear bodies. Indeed, in vivo only the CC-RARα chimera induces efficiently APL in a murine transplantation model. Thus, the PML CC domain represents the minimal structural determinant indispensable to transform RARα into an oncogenic protein.

AB - In acute promyelocytic leukemia (APL) the retinoic acid receptor alpha (RARα) becomes an oncogene through the fusion with several partners, mostly with promyelocytic leukemia protein (PML), all of which have in common the presence of a self-association domain. The new fusion proteins, therefore, differently from the wild-type RARα, which forms only heterodimers with retinoic X receptor alpha, are also able to homo-oligomerize. The presence of such a domain has been suggested to be crucial for the leukemogenic potential of the chimeric proteins found in APL blasts. Whether or not any self-association domain is sufficient to bestow a leukemogenic activity on RARα is still under investigation. In this work, we address this question using two different X-RARα chimeras, where X represents the coiled-coil domain of PML (CC-RARα) or the oligomerization portion of the yeast transcription factor GCN4 (GCN4-RARα). We demonstrate that in vitro both proteins have transforming potential, and recapitulate the main PML-RARα biological properties, but CC-RARα is uniquely able to disrupt PML nuclear bodies. Indeed, in vivo only the CC-RARα chimera induces efficiently APL in a murine transplantation model. Thus, the PML CC domain represents the minimal structural determinant indispensable to transform RARα into an oncogenic protein.

KW - APL

KW - CCR

KW - coiled-coil

KW - GCR

KW - PR

KW - RARa oligomerization

UR - http://www.scopus.com/inward/record.url?scp=79955871887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955871887&partnerID=8YFLogxK

U2 - 10.1038/leu.2011.18

DO - 10.1038/leu.2011.18

M3 - Article

VL - 25

SP - 814

EP - 820

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 5

ER -